GERON CORP (GERN)
US3741631036 - Common Stock
Overall GERN gets a fundamental rating of 2 out of 10. We evaluated GERN against 588 industry peers in the Biotechnology industry. GERN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GERN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year GERN has reported negative net income.
In the past year GERN has reported a negative cash flow from operations.
In the past 5 years GERN always reported negative net income.
In the past 5 years GERN always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of GERN (-46.73%) is comparable to the rest of the industry.
GERN has a Return On Equity of -74.26%. This is comparable to the rest of the industry: GERN outperforms 54.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.73% | ||
| ROE | -74.26% | ||
| ROIC | N/A |
ROA(3y)-57.52%
ROA(5y)-48.38%
ROE(3y)-114.5%
ROE(5y)-86.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GERN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GERN has more shares outstanding
Compared to 5 years ago, GERN has more shares outstanding
GERN has a better debt/assets ratio than last year.
2.2 Solvency
GERN has an Altman-Z score of 2.40. This is not the best score and indicates that GERN is in the grey zone with still only limited risk for bankruptcy at the moment.
GERN has a better Altman-Z score (2.40) than 72.99% of its industry peers.
GERN has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
GERN has a Debt to Equity ratio of 0.14. This is in the lower half of the industry: GERN underperforms 65.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.4 |
ROIC/WACCN/A
WACC9.07%
2.3 Liquidity
A Current Ratio of 3.16 indicates that GERN has no problem at all paying its short term obligations.
GERN's Current ratio of 3.16 is on the low side compared to the rest of the industry. GERN is outperformed by 64.62% of its industry peers.
A Quick Ratio of 3.16 indicates that GERN has no problem at all paying its short term obligations.
With a Quick ratio value of 3.16, GERN is not doing good in the industry: 63.42% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.16 | ||
| Quick Ratio | 3.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.33% over the past year.
GERN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -60.51%.
The Revenue for GERN have been decreasing by -26.03% on average. This is quite bad
EPS 1Y (TTM)8.33%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q10%
Revenue 1Y (TTM)-60.51%
Revenue growth 3Y-1.76%
Revenue growth 5Y-26.03%
Revenue growth Q2Q-77%
3.2 Future
GERN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.26% yearly.
The Revenue is expected to grow by 409.30% on average over the next years. This is a very strong growth
EPS Next Y-2.41%
EPS Next 2Y21.43%
EPS Next 3Y35.25%
EPS Next 5Y32.26%
Revenue Next Year18734.5%
Revenue Next 2Y2886.39%
Revenue Next 3Y1137.91%
Revenue Next 5Y409.3%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GERN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GERN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GERN's earnings are expected to grow with 35.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.43%
EPS Next 3Y35.25%
5. Dividend
5.1 Amount
GERN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GERON CORP
NASDAQ:GERN (4/19/2024, 12:04:08 PM)
3.8
+0.07 (+1.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.23B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.73% | ||
| ROE | -74.26% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.16 | ||
| Quick Ratio | 3.16 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)8.33%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-2.41%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-60.51%
Revenue growth 3Y-1.76%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y